Arya Roy, Hematology-Oncology Fellow at Roswell Park Comprehensive Cancer Center, shared a post on X:
“SERENA-6: Establishing a new pathway for utilizing ctDNA for resistant mutations and early treatment changes!
Improvement in PFS: 16 vs 9.2 months, QoL, acceptable toxicity. Qn: Will this improve OS.”
